| Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer MM Heck, R Tauber, S Schwaiger, M Retz, C D’Alessandria, T Maurer, ... European urology 75 (6), 920-926, 2019 | 267 | 2019 |
| Matched-pair comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy I Rauscher, M Krönke, M König, A Gafita, T Maurer, T Horn, K Schiller, ... Journal of nuclear medicine 61 (1), 51-57, 2020 | 220 | 2020 |
| Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA B Feuerecker, R Tauber, K Knorr, M Heck, A Beheshti, C Seidl, ... European urology 79 (3), 343-350, 2021 | 183 | 2021 |
| Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study A Gafita, J Calais, TR Grogan, B Hadaschik, H Wang, M Weber, S Sandhu, ... The Lancet Oncology 22 (8), 1115-1125, 2021 | 164 | 2021 |
| qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68Ga-PSMA11 PET/CT A Gafita, M Bieth, M Krönke, G Tetteh, F Navarro, H Wang, E Günther, ... Journal of Nuclear Medicine 60 (9), 1277-1283, 2019 | 106 | 2019 |
| Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study A Gafita, I Rauscher, M Weber, B Hadaschik, H Wang, WR Armstrong, ... Journal of Nuclear Medicine 63 (11), 1651-1658, 2022 | 96 | 2022 |
| Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2) R Seifert, L Emmett, SP Rowe, K Herrmann, B Hadaschik, J Calais, ... European Urology 83 (5), 405-412, 2023 | 90 | 2023 |
| Deep neural network for automatic characterization of lesions on 68Ga-PSMA-11 PET/CT Y Zhao, A Gafita, B Vollnberg, G Tetteh, F Haupt, A Afshar-Oromieh, ... European journal of nuclear medicine and molecular imaging 47, 603-613, 2020 | 90 | 2020 |
| One-stop-shop whole-body 68Ga-PSMA-11 PET/MRI compared with clinical nomograms for preoperative T and N staging of high-risk prostate cancer M Thalgott, C Düwel, I Rauscher, MM Heck, B Haller, A Gafita, ... Journal of Nuclear Medicine 59 (12), 1850-1856, 2018 | 70 | 2018 |
| Shape-aware complementary-task learning for multi-organ segmentation F Navarro, S Shit, I Ezhov, J Paetzold, A Gafita, JC Peeken, SE Combs, ... Machine Learning in Medical Imaging: 10th International Workshop, MLMI 2019 …, 2019 | 68 | 2019 |
| The added value of PSMA PET/MR radiomics for prostate cancer staging EL Solari, A Gafita, S Schachoff, B Bogdanović, A Villagrán Asiares, ... European journal of nuclear medicine and molecular imaging 49 (2), 527-538, 2022 | 57 | 2022 |
| Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria A Gafita, I Rauscher, WP Fendler, V Murthy, W Hui, WR Armstrong, ... European Journal of Nuclear Medicine and Molecular Imaging 49 (12), 4271-4281, 2022 | 55 | 2022 |
| Tumor sink effect in 68Ga-PSMA-11 PET: myth or reality? A Gafita, H Wang, A Robertson, WR Armstrong, R Zaum, M Weber, ... Journal of Nuclear Medicine 63 (2), 226-232, 2022 | 55 | 2022 |
| Joint imaging platform for federated clinical data analytics J Scherer, M Nolden, J Kleesiek, J Metzger, K Kades, V Schneider, ... JCO clinical cancer informatics 4, 1027-1038, 2020 | 55 | 2020 |
| Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study A Gafita, WP Fendler, W Hui, S Sandhu, M Weber, R Esfandiari, J Calais, ... European Urology 78 (2), 148-154, 2020 | 51 | 2020 |
| Early prostate-specific antigen changes and clinical outcome after 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer A Gafita, MM Heck, I Rauscher, R Tauber, L Cala, C Franz, ... Journal of Nuclear Medicine 61 (10), 1476-1483, 2020 | 46 | 2020 |
| 68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study A Farolfi, A Gafita, J Calais, M Eiber, A Afshar-Oromieh, F Spohn, ... The Journal of urology 202 (6), 1174-1181, 2019 | 46 | 2019 |
| Whole-body uptake classification and prostate cancer staging in 68Ga-PSMA-11 PET/CT using dual-tracer learning N Capobianco, L Sibille, M Chantadisai, A Gafita, T Langbein, G Platsch, ... European journal of nuclear medicine and molecular imaging, 1-10, 2022 | 45 | 2022 |
| Outcome of patients with PSMA PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis M Hotta, A Gafita, J Czernin, J Calais Journal of Nuclear Medicine 63 (10), 1484-1488, 2022 | 43 | 2022 |
| Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the … J Calais, A Gafita, M Eiber, WR Armstrong, J Gartmann, P Thin, K Nguyen, ... Journal of Nuclear Medicine 62 (10), 1440-1446, 2021 | 43 | 2021 |
